Naslov
How to Optimally Sequence Available Therapy Lines in Advanced Prostate Cancer

Autori
Antunac, Katarina ; Beketić-Orešković, Lidija

Izvornik
Acta clinica Croatica. Supplement (0353-9474) 61 (2022); 32-44

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
Advanced prostate cancer ; hormone sensitive prostate cancer ; castration resistant prostate cancer ; androgen deprivation therapy ; docetaxel ; cabazitaxel ; Radium 223 ; enzalutamide ; apalutamide ; darolutamide ; abiraterone.
(Advanced prostate cancer ; hormone sensitive prostate cancer ; castration resistant prostate cancer ; androgen deprivation therapy ; docetaxel ; cabazitaxel ; Radium 223 ; enzalutamide ; apalutamide ; darolutamide ; abiraterone)

Sažetak
Optimal sequencing of available therapy lines in patients with advanced prostate cancer often poses quite a challenge. The guidelines are sometimes equivocal and clinical trial data are not always applicable to a particular patient. There is a difference in availability of therapy options throughout the world. In decision making, a patient as a whole should be taken into consideration, not just the stage and biology of the disease, but also patient’s age, performance status, comorbidities, previous therapy lines, drug’s safety profile and patient’s preferences. This review article will show certain therapeutic options in the treatment of advanced hormone-sensitive prostate cancer and cas- tration resistant prostate cancer: non- metastatic and metastatic. An attempt will be made to clarify the optimal sequencing.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA